Johnson & Johnson(JNJ) Stock Research - Grey Stern Research

Johnson & Johnson (JNJ) Stock Analysis

$145.27 (-1.94%)

JNJ Financial Performance


Use the table below to view Johnson & Johnson's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $145.27 -
52 Week Low $140.68 -
52 Week High $168.85 -
Market Cap $349.8 Billion 2/8
Gross Margin 70% 5/8
Profit Margin 12% 5/8
EBITDA margin 32% 3/8
Q3 - 2024 Revenue $22.5 Billion 1/8
Q3 - 2024 Earnings $2.7 Billion 4/8
Q3 - 2024 Free Cash Flow $0 Billion 7/8
Trailing 4 Quarters Revenue $87.7 Billion 1/8
Trailing 4 Quarters Earnings $14.7 Billion 1/8
Quarterly Earnings Growth -90% 8/8
Annual Earnings Growth -65% 6/8
Quarterly Revenue Growth 5% 6/8
Annual Revenue Growth -10% 8/8
Cash On Hand $0 7/8
Short Term Debt $0 7/8
Long Term Debt $0 7/8

Johnson & Johnson Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Johnson & Johnson's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 23.82 6/8
PS 3.99 5/8
PB 4.89 6/8
PC -1.00 7/8
Liabilities to Equity -1.00 8/8
ROA -1.00 8/8
ROE 0.21 5/8
Current Ratio 0.00 8/8
Quick Ratio -0.36 8/8
Long Term Debt to Equity 0.00 7/8
Debt to Equity 0.00 7/8
Burn Rate 0.00 5/8
Cash to Cap 0.00 6/8
CCR 0.00 7/8
EV to EBITDA 49.26 6/8
EV to Revenue 3.99 6/8

Company Details

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

CEO: Mr. Alex Gorsky

Website: https://www.jnj.com

Address: 1 Johnson And Johnson Plz New Brunswick, NEW JERSEY

Exchange: New York Stock Exchange

Industry: Drug Manufacturers—General

Johnson & Johnson Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Johnson & Johnson. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Pfizer Inc. PFE $147.4 Billion
Bristol-Myers Squibb Company BMY $115.8 Billion
Gilead Sciences, Inc. GILD $116.0 Billion
AbbVie Inc. ABBV $299.0 Billion
Merck & Co., Inc. MRK $242.0 Billion
Amgen Inc. AMGN $147.0 Billion
Eli Lilly and Company LLY $715.8 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
JNJ Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 22.5 Billion $2.7 Billion
Q2 2024 $ 22.4 Billion $4.7 Billion
Q1 2024 $ 21.4 Billion $3.3 Billion
Q4 2023 $ 21.4 Billion $4.0 Billion
Q3 2023 $ 21.4 Billion $26.0 Billion
Q2 2023 $ 25.5 Billion $5.1 Billion
Q1 2023 $ 24.7 Billion -$68.0 Million
Q4 2022 $ 23.7 Billion $3.5 Billion

View All

JNJ Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $0 $0 $0 $71.5 Billion
Q2 2024 $24.9 Billion $181.1 Billion $41.5 Billion $71.5 Billion
Q1 2024 $25.5 Billion $172.0 Billion $33.6 Billion $70.0 Billion
Q4 2023 $21.9 Billion $167.6 Billion $30.4 Billion $68.8 Billion
Q3 2023 $19.7 Billion $166.1 Billion $29.9 Billion $71.2 Billion
Q2 2023 $21.2 Billion $191.7 Billion $45.6 Billion $75.1 Billion
Q1 2023 $19.2 Billion $196.0 Billion $52.9 Billion $70.9 Billion
Q4 2022 $14.1 Billion $187.4 Billion $39.7 Billion $76.8 Billion

View All

JNJ Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $0 $0 $0
Q2 2024 $4.7 Billion -$976.0 Million -$595.0 Million
Q1 2024 $2.9 Billion -$807.0 Million $3.6 Billion
Q4 2023 $6.3 Billion -$1.6 Billion $2.1 Billion
Q3 2023 $6.5 Billion -$967.0 Million -$1.5 Billion
Q2 2023 $3.1 Billion -$1.1 Billion -$5.7 Billion
Q1 2023 $2.4 Billion -$863.0 Million $12.7 Billion
Q4 2022 $3.8 Billion -$1.6 Billion $2.8 Billion

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions